XBiotech Inc.

Company Overview

Business Model: XBIOTECH INC. is a biopharmaceutical company focused on the discovery and development of True Human™ monoclonal antibodies for the treatment of various inflammatory and infectious diseases. The Company's proprietary technology enables the isolation and cloning of antibodies from human donors who exhibit natural immune responses, a method distinct from the animal immunization or engineering used for other marketed antibody therapeutics. XBIOTECH INC. operates as a fully integrated developer, possessing its own manufacturing technology and a state-of-the-art research and manufacturing center in Austin, Texas, designed to reduce the cost and time associated with launching new product candidates. A key area of medical focus is the development of therapies that block interleukin-1 alpha (IL-1a), a substance involved in numerous pathophysiological processes including tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and general inflammation. The Company's strategy involves developing different anti-IL-1a antibodies for specific medical areas, allowing for potential separate partnerships or sales for distinct disease indications.

Market Position: XBIOTECH INC. holds a unique position in the antibody therapeutic market by exclusively developing True Human™ monoclonal antibodies, which are derived from natural human immune responses. This approach is believed to offer potential advantages in safety, efficacy, and development speed compared to animal-derived or engineered counterparts that dominate the $247 billion antibody market. The Company identifies a significant unmet medical need for blocking IL-1a, comparable in scale to the market for anti-TNF therapies. In 2019, XBIOTECH INC. sold its True Human™ antibody Bermekimab, targeting IL-1a, for $750 million in cash and up to $600 million in potential milestone payments, while retaining rights to develop new anti-IL-1a antibodies for non-dermatological indications. Janssen Biotech, Inc. also agreed to assert acquired IL-1a patents for XBIOTECH INC.'s benefit in these non-dermatological areas.

Recent Strategic Developments:

• IL-1a Therapeutic Pipeline Expansion: Following the sale of Bermekimab, XBIOTECH INC. quickly identified and advanced new IL-1a targeting product candidates into clinical studies across oncology, rheumatology, and neurology, developing two anti-IL-1a candidates in parallel.
• Oncology Program (Natrunix™): A randomized, double-blinded, placebo-controlled clinical study of Natrunix™ (anti-IL-1a) in pancreatic cancer, initiated in 2021 with 60 subjects, completed its last subject dose in April 2025. Preliminary analysis, announced June 18, 2024, indicated reduced hospitalization, fewer serious adverse events, longer progression-free survival, and less severe diarrhea in Natrunix™-treated patients. The Company believes these findings represent a potentially transformative approach to cancer management and may extend to other solid tumors treated with chemotherapy. Discussions with the FDA regarding a regulatory path are ongoing.
• Rheumatology Program (Natrunix™): A double-blind, placebo-controlled study of Natrunix™ for rheumatoid arthritis, in combination with methotrexate, enrolled 233 subjects and was completed with findings announced on December 23, 2024. However, the data was deemed uninterpretable due to "numerous enrollment irregularities" and "widespread improprieties at clinical sites." XBIOTECH INC. maintains its belief in Natrunix™'s potential for arthritic diseases.
• Neurology Program (Hutrukin): An investigational new drug application for Hutrukin (anti-IL-1a) to reduce brain injury after stroke reperfusion procedures was filed in 2022. A Phase I study, completed at the end of 2023, demonstrated high bolus doses were safe and well tolerated, with data analysis completed in Q1 2024. The planned Phase II study in stroke is currently on hold pending clarification of regulatory paths for the cancer and arthritis programs.
• Infectious Disease Pipeline: XBIOTECH INC. is advancing an infectious disease pipeline, including a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA) and pre-clinical stage therapeutics for C. difficile (oral delivery), varicella zoster (shingles, injectable), and influenza (designed to neutralize all known strains since the 1918 pandemic). The Company is working towards filing investigational new drug applications for its shingles and influenza antibodies in the upcoming year.
• Infrastructure Expansion: In 2022, XBIOTECH INC. completed an expansion of its manufacturing and R&D center, adding new research laboratory and administrative wings. In 2019, a separate facility for infectious disease and animal facilities, including an animal biological safety level 2 (ABSL2) laboratory, was constructed on its Austin campus.
• Leadership Transition: John Simard, the Company's Founder and former Chief Executive Officer, retired from his CEO role on December 8, 2025, but continues to serve as Chairman and in a consulting capacity. Dr. Sushma Shivaswamy, the Chief Scientific Officer, was appointed interim Chief Executive Officer.

Geographic Footprint: XBIOTECH INC. is headquartered in Austin, Texas, where it owns a 48-acre industrial-zoned property housing its state-of-the-art research and manufacturing center, as well as infectious disease and animal facilities. Its wholly-owned subsidiary, XBiotech USA, Inc., is incorporated in Delaware, United States. Substantially all of the Company's operations are conducted within the U.S. geographic segment. The Company is subject to income tax in Canada, the USA, and the state of Texas.

Financial Performance

Revenue Analysis

XBIOTECH INC. has not generated any revenue from commercial product sales to date and does not expect to generate any revenue in the fiscal year 2026. The Company's prior revenue streams from a clinical manufacturing agreement and clinical trial operations services with a Janssen-related company concluded at the end of 2023.

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: N/A
• Net Margin: N/A

Investment in Growth:

• R&D Expenditure: $47.4 million (85% of total operating expenses) in 2025, an increase from $37.8 million (89% of total operating expenses) in 2024. This increase was primarily driven by higher salaries and related expenses, including a significant portion of John Simard's severance and bonus, and increased share-based compensation.
• Capital Expenditures: $0.289 million in 2025, down from $1.304 million in 2024, primarily for fixed asset purchases and preparation for a new facility.
• Strategic Investments: Ongoing investment in the discovery and development of next-generation True Human™ anti-IL-1a antibody programs and other pipeline antibody therapeutics.

Business Segment Analysis

The Company's chief operating decision maker views the Company’s operations and manages its business as one operating segment. Therefore, a detailed breakdown by business segment is not applicable.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: XBIOTECH INC. returned $420 million to shareholders through a modified Dutch auction tender offer in February 2020 and $14 thousand in June 2023.
• Dividend Payments: A $75 million cash dividend ($2.50 per share) was distributed to shareholders in July 2021.
• Dividend Yield: Not provided for the current period.
• Future Capital Return Commitments: The Company currently intends to retain any earnings for future growth and does not expect comparable cash dividends to continue in the foreseeable future. Any future dividend declarations will be at the discretion of the Board of Directors.

Balance Sheet Position:

• Cash and Equivalents: $125.6 million as of December 31, 2025, compared to $172.7 million as of December 31, 2024.
• Total Debt: $0 as of December 31, 2025, reflecting the full repayment of a $10 million convertible loan from John Simard and a $250 thousand convertible loan from a third party on January 31, 2025. Total debt was $10.25 million as of December 31, 2024.
• Net Cash Position: $125.6 million as of December 31, 2025.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The $10 million convertible loan from John Simard, entered into on January 3, 2024, with a contractual maturity of January 3, 2029, was fully repaid on January 31, 2025.

Cash Flow Generation:

• Operating Cash Flow: Net cash used in operating activities was $(39.9) million for the year ended December 31, 2025, compared to $(31.0) million for the year ended December 31, 2024, primarily driven by net losses and increased salaries and related expenses.
• Free Cash Flow: Approximately $(40.2) million in 2025 (Operating Cash Flow of $(39.9) million minus Capital Expenditures of $0.289 million) and approximately $(32.3) million in 2024 (Operating Cash Flow of $(31.0) million minus Capital Expenditures of $1.304 million).
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: XBIOTECH INC. employs a fully integrated operational philosophy encompassing the discovery, development, and manufacturing of its True Human™ monoclonal antibodies. The Company leverages its proprietary technical know-how to translate natural human immunity into therapeutic product candidates. Its operations are centered at a state-of-the-art research and manufacturing facility in Austin, Texas. Historically, XBIOTECH INC. utilized its manufacturing plant and infrastructure to produce drug product under a supply agreement for a world-leading pharmaceutical company and provided clinical trial operations services for two Phase II clinical studies from 2020 through the end of 2023, when these agreements concluded.

Supply Chain Architecture: Key Suppliers & Partners:

• Clinical Trial Service Providers: Third-party service providers are contracted to conduct and manage clinical trials on the Company’s behalf.
• Waste Disposal Services: Third parties are engaged for the disposal of hazardous materials and wastes generated from operations.
• Component Suppliers: The Company relies on third parties to supply various items critical for producing its product candidates.

Facility Network:

• Manufacturing & Research and Development: The Company owns a 48-acre industrial-zoned property in Austin, Texas, which houses its combined R&D and manufacturing facility. This facility underwent an expansion in 2022, adding new state-of-the-art research laboratories and administrative space.
• Infectious Disease & Animal Facilities: A separate building on the Austin campus, constructed in 2019, incorporates an animal biological safety level 2 (ABSL2) laboratory and other laboratories dedicated to developing and testing True Human™ antibodies against infectious disease targets.
• Ownership: XBIOTECH INC. owns the entire 48-acre campus and all structures on the property debt-free, with plans for further expansion.

Operational Metrics:

• Depreciation expenses related to property and equipment amounted to approximately $1.7 million for both the years ended December 31, 2025, and 2024.
• Construction in process, related to research and development, manufacturing equipment, and design plans for an operating facility, totaled $1.792 million as of December 31, 2025, compared to $1.705 million as of December 31, 2024.

Market Access & Customer Relationships

Go-to-Market Strategy: XBIOTECH INC. does not currently possess a comprehensive internal infrastructure for the sales, marketing, and distribution of pharmaceutical drug products. The Company's future commercialization strategy will depend on either building out these internal capabilities or establishing arrangements with third parties to perform these services.

Customer Portfolio: As a pre-market pharmaceutical company, XBIOTECH INC. has not generated any revenue from commercial product sales to date. The Company previously had a supply agreement and provided clinical trial operations services for a world-leading pharmaceutical company (a Janssen-related entity) from 2020 through the end of 2023.

Geographic Revenue Distribution: The Company has no product revenue. Substantially all of XBIOTECH INC.'s operations are conducted within the U.S. geographic segment.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biopharmaceutical industry is characterized by intense competition in the development and commercialization of new drug products. The antibody therapeutic market is substantial, valued at $247 billion. The standard of care for many diseases is continuously evolving due to ongoing therapeutic advancements.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: XBIOTECH INC. faces competition from numerous large pharmaceutical and biotechnology companies that are actively marketing or developing products for the same disease indications. This competitive landscape also includes academic institutions, government agencies, and other public and private research organizations. Many competitors possess significantly greater financial, technical, and human resources, which may enable them to obtain regulatory approval and commercialize products more quickly.

Emerging Competitive Threats: The industry is subject to continuous innovation, with new therapeutics constantly being developed that could supplant or expand upon existing standards of care. The Company must contend with the potential for new entrants, disruptive technologies, and alternative solutions from well-resourced and experienced competitors.

Competitive Response Strategy: XBIOTECH INC.'s strategy to maintain competitive advantage centers on its unique True Human™ antibody discovery technology and its diverse pipeline of product candidates targeting both inflammatory and infectious diseases. The Company's proprietary manufacturing technology aims to provide a cost and time advantage. Furthermore, its strategic approach to IL-1a therapies involves developing distinct antibodies for specific medical areas, which could facilitate separate partnerships or sales for different indications.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Regulatory Approval: Future success is substantially dependent on obtaining regulatory approval for product candidates, a process that is lengthy, time-consuming, inherently unpredictable, and never guaranteed. Approvals may come with significant limitations or be denied.
• Market Acceptance: Even if regulatory approval is obtained, product candidates may not achieve adequate market acceptance among physicians, patients, and healthcare payers, which is critical for commercial success.
• Competition: The Company faces substantial competition from larger, more established pharmaceutical and biotechnology companies with greater resources, which could lead to competitors commercializing products before XBIOTECH INC.
• Product Revenue & Profitability: XBIOTECH INC. currently has no source of product revenue and may never sustain profitability.
• Milestone Payments: The Company may not receive the potential $600 million in milestone payments from the Janssen Transaction, as these are subject to Janssen Biotech, Inc.'s business decisions, discretion, and regulatory approvals, which are outside XBIOTECH INC.'s control.
• Research Program Failure: There is a significant risk that research programs may fail at various stages, including inability to develop, lack of regulatory approval, unexpected clinical trial events, or insufficient data.
• Commercial Success: Even an effective drug candidate, as determined by regulatory authorities, may not be commercially successful due to competitive products, rare disease indications, or insufficient buy-in from patients and healthcare professionals, or lack of reimbursement.
• New Laws or Regulations: Changes in government laws or regulations in the U.S., Europe, or other jurisdictions could impact the Company's ability to receive necessary approvals for marketing and commercialization.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: XBIOTECH INC. relies on third parties to supply crucial components for manufacturing product candidates. Disruptions to these suppliers due to natural disasters, public health crises, or other business interruptions could severely impact the Company's ability to produce clinical supplies.
• Geographic Concentration: The Company's operations are concentrated in Austin, Texas, making it disproportionately vulnerable to negative impacts from major natural disasters, public health threats (such as the coronavirus pandemic), or man-made disasters in that region. Capacity Constraints: Not explicitly detailed, but the Company acknowledges the need to expand operations and grow its organization in the future, which could present management challenges.

Financial & Regulatory Risks

Market & Financial Risks:

• Significant Losses: XBIOTECH INC. has incurred significant losses since its inception and expects to continue incurring operating losses for the foreseeable future as it advances drug candidates.
• Additional Capital: The Company may require substantial additional capital to complete clinical development and potential commercialization activities. Future financing may not be available in sufficient amounts or on terms acceptable to XBIOTECH INC., if at all.
• Product Liability: The Company faces an inherent risk of product liability exposure from testing product candidates in clinical trials and, if approved, from commercial sales. Successful claims could result in substantial liabilities, decreased demand, or reputational harm.
• Share Price Volatility: The Company's stock price may be subject to wide fluctuations in response to clinical trial results, regulatory actions, financial performance, competitive developments, and general economic and market conditions.
• Capital Allocation: Management has broad discretion in the use of net proceeds from the Janssen Transaction and public offerings, and there is a risk that these funds may not be used effectively.
• NOL and Tax Credit Limitations: XBIOTECH INC. has net operating loss (NOL) and research tax credit carryforwards, but their utilization may be limited in the future due to substantial changes in the Company’s ownership under Section 382 of the Internal Revenue Code.
• Foreign Exchange: The Company is exposed to foreign exchange gains and losses due to fluctuations between the U.S. dollar and the Canadian dollar, impacting interest income from Canadian bank accounts. Credit & Liquidity: The Company's principal sources of liquidity are its cash and cash equivalents, and its ability to fund operations depends on these resources and future cash receipts.

Regulatory & Compliance Risks:

• Ongoing Regulatory Oversight: Even if product candidates receive marketing approval, they will be subject to ongoing and extensive requirements by the FDA and comparable foreign regulatory authorities governing manufacture, quality control, labeling, safety surveillance, and promotion.
• Undesirable Side Effects: Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences (e.g., marketing suspension, withdrawal of approval, lawsuits) following marketing approval.
• Off-Label Promotion: Engaging in impermissible promotion of future products for unapproved or off-label uses could subject the Company to enforcement actions, false claims litigation, and significant penalties.
• Foreign Regulatory Approval: Failure to obtain separate marketing approvals and comply with numerous and varying regulatory requirements in foreign jurisdictions (e.g., European Union) would prevent product candidates from being marketed in those regions.
• Environmental, Health and Safety: Failure to comply with numerous environmental, health, and safety laws and regulations could lead to fines, penalties, or significant costs.
• Internal Control over Financial Reporting: Failure to maintain an effective system of internal control over financial reporting could lead to inaccurate financial reports or fraud, harming business and stock price.

Geopolitical & External Risks

Geopolitical Exposure:

• Policy and Trade Decisions: Policy and trade decisions made by governments in jurisdictions where XBIOTECH INC. operates, including the United States and Canada, could materially impact the macroeconomic framework, supply chains, and financial condition (e.g., through tariffs or changes in trade policies).
• Geographic Dependencies: The concentration of operations in Austin, Texas, makes the Company susceptible to localized geopolitical or external risks.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• True Human™ Monoclonal Antibodies: XBIOTECH INC.'s core technology focuses on the rapid identification and cloning of True Human™ antibodies from individuals who have demonstrated natural immunity or resistance to specific diseases. This proprietary technical know-how is central to translating natural human immunity into therapeutic product candidates.
• Interleukin-1 Alpha (IL-1a) Therapies: A significant area of focus is the development of new IL-1a targeting product candidates, with ongoing clinical studies in oncology, rheumatology, and neurology.
• Anti-Infective Antibodies: The Company is dedicated to advancing its infectious disease pipeline, identifying and developing True Human™ anti-infective antibody therapies for areas of urgent unmet medical need.

Innovation Pipeline:

• Oncology: Natrunix™ (anti-IL-1a) is in clinical study for pancreatic cancer, with promising preliminary efficacy and safety data, and potential applicability to other solid tumors.
• Rheumatology: Natrunix™ (anti-IL-1a) was investigated in a clinical study for rheumatoid arthritis, though the data was deemed uninterpretable due to site improprieties. The Company continues to believe in its potential.
• Neurology: Hutrukin (anti-IL-1a) has completed a Phase I study for reducing brain injury after stroke reperfusion procedures, demonstrating safety and tolerability. A Phase II study is on hold pending regulatory clarity for other programs.
• Infectious Disease: The pipeline includes a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and pre-clinical stage therapeutics for oral delivery against C. difficile, an injectable therapy for varicella zoster (shingles), and a broad-spectrum influenza therapy. The Company is working towards filing INDs for its shingles and influenza antibodies in the upcoming year.

Intellectual Property Portfolio:

• Patent Strategy: XBIOTECH INC. relies on a combination of trade secret, patent, copyright, and trademark laws to protect its proprietary technology. The Company actively files patent applications in the U.S. and internationally for its novel technologies and products.
• Licensing Programs: As part of the Janssen Transaction, Janssen Biotech, Inc. agreed to assert all patents it acquired relating to IL-1a for the benefit of XBIOTECH INC. to protect its future IL-1a-related therapies in all non-dermatological indications.
• IP Litigation: The Company acknowledges the risk of third parties asserting claims or initiating litigation related to their intellectual property rights.

Technology Partnerships:

• XBIOTECH INC. previously engaged in a clinical manufacturing agreement and provided clinical trial operations services for a Janssen-related company, which concluded at the end of 2023.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The senior management team, on average, has been with XBIOTECH INC. for over 13 years, contributing collective knowledge across antibody discovery, manufacturing, preclinical development, regulatory submissions, and commercial sale. John Simard, the Company's founder, retired as Chief Executive Officer on December 8, 2025, but continues in a consulting role and as Chairman. Dr. Sushma Shivaswamy, the Chief Scientific Officer, has assumed the role of interim Chief Executive Officer.

Board Composition: The Board of Directors includes individuals with significant industry, scientific, and legal knowledge. Specific details regarding board independence, expertise areas, and committee structure are incorporated by reference to the Company's Proxy Statement.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2025, XBIOTECH INC. had 85 full-time employees.
• Geographic Distribution: Not explicitly detailed, but substantially all operations are in the U.S.
• Skill Mix: The workforce includes personnel in managerial, operational, sales, marketing, scientific, and financial functions, supporting drug development and other activities.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The Company operates in a competitive industry with high demand for experienced employees.
• Retention Metrics: Not explicitly provided.
• Employee Value Proposition: XBIOTECH INC. offers competitive salaries, stock option awards (upon initial hiring and annually), and annual bonuses contingent on corporate and/or personal objectives, alongside comprehensive compensation, leave, and benefits programs designed to attract and retain talented and experienced employees.

Diversity & Development:

• Diversity Metrics: Not explicitly provided.
• Development Programs: Not explicitly detailed.
• Culture & Engagement: The Company maintains an Employee Handbook outlining corporate policies and guidelines for professional behavior, including a Code of Business Conduct and Ethics.

Environmental & Social Impact

Environmental Commitments: Supply Chain Sustainability: XBIOTECH INC.'s operations involve the use of hazardous and flammable materials, including chemicals and biological materials, and produce hazardous waste products. The Company contracts with third parties for the disposal of these materials and wastes.

Social Impact Initiatives:

• Product Impact: XBIOTECH INC. believes its True Human™ antibodies, as analogues of natural immunity, may serve as an effective means for supplementing infectious immunity in compromised individuals (e.g., the elderly, young children) or in otherwise healthy individuals whose natural immunity has been overwhelmed by infectious agents.

Business Cyclicality & Seasonality

No material information explicitly stated in the filing to populate this section.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: XBIOTECH INC. operates within a highly regulated pharmaceutical and biotechnology industry, subject to numerous state, federal, and international laws, regulations, and court decisions. The Company must ensure its strategies and planning align with current regulations. Manufacturers of drug products and their facilities are subject to continual review and periodic inspections for compliance with current good manufacturing practices (cGMP) and other regulations. International Compliance: To market and sell products in the European Union and other jurisdictions, XBIOTECH INC. must obtain separate marketing approvals and comply with varying regulatory requirements, a process that can involve additional testing and significant delays.

Trade & Export Controls:

• Trade Relations: Policy and trade decisions by government entities, including the United States and Canada, could affect the macroeconomic framework in which XBIOTECH INC. operates and impact its business and financial condition, potentially through tariffs or other changes in trade policies.

Legal Proceedings: XBIOTECH INC. is not currently subject to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The Company's effective tax rate was -0.52% for the year ended December 31, 2025, and 0.08% for the year ended December 31, 2024. The primary drivers of the variance from the statutory rate were losses in jurisdictions for which a valuation allowance is recorded.
• Geographic Tax Planning: XBIOTECH INC. is subject to income tax in multiple jurisdictions, including Canada, the USA, and the state of Texas. The Company considers all foreign earnings to be permanently reinvested.
• Tax Reform Impact: In 2025, the Company received and recognized $558 thousand related to the Employee Retention Credit from the Internal Revenue Service, a provision of the CARES Act.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the Company had federal NOL carryforwards of $2.1 million (with an indefinite carryforward period) and foreign NOL carryforwards of $54.6 million (with a limited carryforward period, beginning to expire in 2044). State post-apportioned NOL carryforwards were $0.
• Research and Other Credits: The Company had research and other credits of $10.35 million as of December 31, 2025, compared to $9.15 million as of December 31, 2024.
• Valuation Allowance: A full valuation allowance of $33.891 million was recorded against deferred tax assets as of December 31, 2025, as the Company determined it was more likely than not that some portion of the deferred tax assets would not be realized, primarily due to historical pretax net losses.
• Unrecognized Tax Benefits: As of December 31, 2025, unrecognized tax benefits totaled $3.716 million, with accrued interest and penalties of $414 thousand.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: XBIOTECH INC. maintains insurance coverage for employee injury. However, the Company does not maintain insurance for environmental liability or toxic tort claims. If marketing approval for its product candidates is obtained, the Company plans to secure insurance coverage for the sale of commercial products.
• Risk Transfer Mechanisms: The Company is predominantly self-insured for business disruptions that may arise from natural disasters, infrastructure interruptions, or other public health threats.